Genzyme Purchase Of Cell Genesys Shows Confidence In Gene Therapy Future
Executive Summary
Genzyme's $350 mil. acquisition of Cell Genesys represents a vote of confidence in gene therapy after concerns about the death of a clinical trial subject.
You may also be interested in...
TKT Hemophilia Gene Therapy Trial Halted Despite No Evidence Of Problems
The suspension of Transkaryotic Therapies' gene therapy trial at Beth Israel Deaconess Medical Center could signal the beginning of a trend of gene therapy trial suspensions as a cautionary measure even if the study shows no sign of problems.
TKT Hemophilia Gene Therapy Trial Halted Despite No Evidence Of Problems
The suspension of Transkaryotic Therapies' gene therapy trial at Beth Israel Deaconess Medical Center could signal the beginning of a trend of gene therapy trial suspensions as a cautionary measure even if the study shows no sign of problems.
Vical Is Vital On Wall Street After Adenoviral Vector Problems
Vical's "naked DNA" vectorless gene therapy technology helped the company outstrip a strong market for biotech stocks and post a 50% gain for the month of November.